Seattle Genetics Inc. | Mutual Funds
Mutual Funds that own Seattle Genetics Inc.
PRIMECAP Odyssey Growth Fund
6,118,700
3.85%
594,270
3.49%
06/30/2018
PRIMECAP Odyssey Aggressive Growth Fund
4,205,500
2.65%
396,100
2.87%
06/30/2018
American Funds New Perspective Fund
3,743,903
2.36%
0
0.35%
06/30/2018
Vanguard Total Stock Market Index Fund
2,581,461
1.63%
2,760
0.03%
07/31/2018
Vanguard Capital Opportunity Fund
2,424,900
1.53%
15,000
0.99%
06/30/2018
T Rowe Price Mid Cap Growth Fund
1,963,743
1.24%
213,743
0.46%
06/30/2018
Vanguard Health Care Fund
1,911,900
1.2%
0
0.28%
06/30/2018
iShares Nasdaq Biotechnology ETF
1,829,320
1.14%
-23,919
1.43%
09/06/2018
T Rowe Price Mid Cap Value Fund
1,706,582
1.08%
-62,600
0.96%
06/30/2018
American Funds Insurance Series - Growth Income Fund
1,536,306
0.97%
0
0.4%
06/30/2018
| Address |
21823 30th Drive SE
Bothell Washington 98021
United States
|
|
Employees
|
- |
| Website |
http://www.seattlegenetics.com |
| Updated |
07/08/2019 |
| Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. |
